<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transverse myelitis: Etiology, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transverse myelitis: Etiology, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transverse myelitis: Etiology, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin Greenberg, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12689875"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute transverse myelitis (TM) is a rare, acquired neuroimmune spinal cord disorder that can present with the rapid onset of weakness, sensory alterations, and bowel or bladder dysfunction. TM can occur as an independent entity, usually as a postinfectious complication, but TM also exists on a continuum of neuroinflammatory disorders that includes acute disseminated encephalomyelitis (ADEM), multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and acute flaccid myelitis (AFM).</p><p>This topic will review the etiology, clinical features, and diagnosis of TM. Treatment and prognosis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/142457.html" rel="external">"Transverse myelitis: Treatment and prognosis"</a>.)</p><p>Related conditions are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/14087.html" rel="external">Acute disseminated encephalomyelitis (ADEM) in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/126102.html" rel="external">Acute flaccid myelitis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">Evaluation and diagnosis of multiple sclerosis in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">Manifestations of multiple sclerosis in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis</a></p><p></p><p class="headingAnchor" id="H3396374832"><span class="h1">TERMINOLOGY AND CLASSIFICATION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myelopathy</strong> – A clinical syndrome characterized by motor, sensory, or autonomic symptoms caused by spinal cord dysfunction [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myelitis</strong> – Inflammation of the spinal cord.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transverse myelitis (TM)</strong> – In the strictest sense, TM is defined as inflammation involving an entire transverse section of the spinal cord. However, TM is also used to refer to immune-mediated myelitis involving all or part of a transverse section of the spinal cord, also referred to as a segmental syndrome [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2">We use the term TM inclusively to comprise all causes of inflammatory myelopathy, regardless of the severity or degree of structural or functional interruption of pathways through a transverse spinal cord section [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Idiopathic TM</strong> – When the cause of TM is not identified despite a comprehensive evaluation, the TM is referred to as idiopathic. (See <a class="local">'Idiopathic'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary (disease-related) TM</strong> – When TM is associated with other immune-mediated conditions (see <a class="local">'Associated and causative conditions'</a> below), it is considered secondary or disease-related TM. The clinical features, diagnostic work-up, and acute and chronic therapies differ between these forms of TM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtypes</strong> – Subtypes of TM are differentiated based upon the clinical severity, relative involvement of spinal cord gray matter, and longitudinal extent of the spinal cord lesion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute partial TM</strong> – Spinal cord dysfunction that is mild or grossly asymmetric with a magnetic resonance imaging (MRI) lesion extending one to two vertebral segments.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute complete TM</strong> – Spinal cord dysfunction that causes symmetric, complete, or near complete neurologic deficits (paresis, sensory loss, and autonomic dysfunction) below the level of the lesion with a corresponding lesion on MRI that extends one to two vertebral segments.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Longitudinally extensive transverse myelitis (LETM)</strong> – Complete or incomplete spinal cord dysfunction with a corresponding lesion on MRI that extends three or more vertebral segments.</p><p></p><p class="bulletIndent1">These subtypes of TM, while imperfect, imply distinct differential diagnoses and prognoses.</p><p></p><p class="headingAnchor" id="H190496924"><span class="h1">IMMUNOPATHOGENESIS</span><span class="headingEndMark"> — </span>The immunopathogenesis of TM is varied and reflects the rather diverse spectrum of this disease from idiopathic to disease-associated myelitis. (See <a class="local">'Associated and causative conditions'</a> below.)</p><p>Traditionally, the majority of TM cases were thought to be characterized by perivascular infiltration by monocytes and lymphocytes in the lesion [<a href="#rid4">4</a>]. Axonal degeneration was also reported [<a href="#rid4">4</a>]. Autopsy reports have described lymphocytic infiltration with demyelination and axonal loss [<a href="#rid5">5</a>]. Pathologic heterogeneity and the involvement of both gray and white matter suggest that TM is not a pure demyelinating disorder but rather a mixed inflammatory disorder that affects neurons, axons, and oligodendrocytes and myelin.</p><p>In parainfectious TM, the injury may be associated with the systemic response to infection by a variety of agents such as enteroviruses, varicella zoster virus (VZV), herpes virus, and Listeria monocytogenes  (<a class="graphic graphic_table graphicRef121798" href="/z/d/graphic/121798.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef121799" href="/z/d/graphic/121799.html" rel="external">table 2</a>) [<a href="#rid6">6</a>],and only rarely with direct microbial infection of the central nervous system (CNS)<em>. </em>Molecular mimicry and super antigen-mediated disease have also been described as potential mechanisms of autoimmunity [<a href="#rid5">5</a>]. Molecular mimicry in TM was postulated to be the cause of injury following infection with <em>Enterobius vermicularis </em>(pinworm) in a patient who had elevated titers of cross-reacting antibodies [<a href="#rid7">7</a>]. Microbial superantigens such as staphylococcal enterotoxins A through I, toxic shock syndrome toxin-1, and streptococcus pyogenes exotoxin, have also been purported to stimulate the immune system and are known to be capable of activating T-lymphocytes without costimulatory molecules [<a href="#rid5">5,8-11</a>], thereby triggering autoimmune disease by activating preexisting autoreactive T cell clones [<a href="#rid12">12,13</a>].</p><p>The diverse pathology of disease-associated TM is evident from studies showing that lupus-associated TM could be associated with CNS vasculitis or thrombotic infarction of the spinal cord [<a href="#rid5">5,14-18</a>]. Other studies have also described the role of autoantibodies in patients with neuromyelitis optica spectrum disorder (NMOSD) and recurrent TM [<a href="#rid19">19-22</a>]. Autoantibodies have been implicated in activating other components of the immune system after crossing the blood-brain barrier. It may also be that some autoantibodies initiate a direct and selective injury of neurons or glia that express antigens with epitopes, which cross-react with antibodies directed against infectious pathogens [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H202896339"><span class="h1">ASSOCIATED AND CAUSATIVE CONDITIONS</span><span class="headingEndMark"> — </span>TM exists on a continuum of neuroinflammatory disorders. In a retrospective report from a tertiary center that included 1193 patients referred between 2006 and 2021 for evaluation of TM, an inflammatory myelopathy was diagnosed in 772 patients (65 percent) and a noninflammatory myelopathy in 421 (35 percent) [<a href="#rid23">23</a>]. In the 772 patients with an inflammatory myelopathy, the most frequent diagnoses after a comprehensive work-up were multiple sclerosis or clinically isolated syndrome in 221 (29 percent), idiopathic myelitis in 149 (19 percent), and neuromyelitis optica spectrum disorder (NMOSD) in 132 (17 percent).</p><p class="headingAnchor" id="H40026167"><span class="h2">CNS demyelinating disorders</span><span class="headingEndMark"> — </span>Central nervous system (CNS) demyelinating disorders that can cause TM include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple sclerosis</strong> – TM can occur as part of the spectrum of multiple sclerosis. In some cases, TM is the initial demyelinating event (a clinically isolated syndrome) that precedes clinically definite multiple sclerosis. (See  <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">"Manifestations of multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromyelitis optica spectrum disorder (NMOSD)</strong> – TM manifesting as a longitudinally extensive spinal cord lesion spanning three or more vertebral segments is one of the characteristic manifestations, along with optic neuritis, of NMOSD. However, NMOSD can also cause TM involving fewer segments. The most common autoantibody identified in NMOSD is the anti-aquaporin-4 (AQP4) antibody. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'Transverse myelitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)</strong> – This disorder is associated with a variety of manifestations related to CNS demyelination that include relapsing and bilateral optic neuritis, TM, brainstem encephalitis, and acute disseminated encephalomyelitis (ADEM). MOGAD is more common in children than adults and can mimic the NMOSD syndrome seen in patients with the anti-AQP4 antibody. (See  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute disseminated encephalomyelitis (ADEM) </strong>– TM may be seen in patients with ADEM, a demyelinating disease of the CNS that typically presents as a monophasic disorder with multifocal neurologic symptoms and encephalopathy. Brain involvement is required to make a diagnosis of ADEM. (See  <a class="medical medical_review" href="/z/d/html/14087.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2576533226"><span class="h2">Systemic autoimmune disorders</span><span class="headingEndMark"> — </span>The systemic inflammatory autoimmune disorders more commonly associated with TM include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis [<a href="#rid24">24-26</a>] (see  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis", section on 'Brain and spinal cord involvement'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sjögren's disease [<a href="#rid27">27-29</a>] (see  <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">"Neurologic manifestations of Sjögren's disease", section on 'Focal or multifocal demyelination/inflammation'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus [<a href="#rid27">27,30,31</a>] (see  <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">"Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Inflammatory and demyelinating disease'</a>)</p><p></p><p class="bulletIndent1">Less commonly associated systemic inflammatory autoimmune disorders include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ankylosing spondylitis [<a href="#rid32">32</a>] (see  <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">"Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Neurologic manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid syndrome [<a href="#rid27">27,33,34</a>] (see  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Neurologic involvement'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behçet syndrome [<a href="#rid35">35,36</a>] (see  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome", section on 'Neurologic disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed connective tissue disease [<a href="#rid37">37</a>] (see  <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">"Mixed connective tissue disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/z/d/html/7480.html" rel="external">"Neurologic manifestations of rheumatoid arthritis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic sclerosis [<a href="#rid39">39</a>] (see  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>)</p><p></p><p class="headingAnchor" id="H95375166"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Infections associated with TM include but are not limited to enteroviruses (commonly enterovirus D68 and EV71, and poliovirus), West Nile virus, herpes viruses, human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV-1), Zika virus [<a href="#rid40">40</a>], neuroborreliosis (Lyme), <em>Mycoplasma</em>, and <em>Treponema pallidum</em>  (<a class="graphic graphic_table graphicRef121798" href="/z/d/graphic/121798.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef121799" href="/z/d/graphic/121799.html" rel="external">table 2</a>).</p><p>Acute flaccid myelitis (AFM) is a specific neurologic condition recognized in biennial outbreaks in the United States and Europe associated with circulating enterovirus D68. AFM manifests as a clinical syndrome similar to poliomyelitis with a gray matter-centric myelitis and a lower motor neuron pattern of weakness (eg, reduced reflexes, decreased tone). Most cases have occurred in children; adults are rarely affected. (See  <a class="medical medical_review" href="/z/d/html/126102.html" rel="external">"Acute flaccid myelitis"</a>.)</p><p>In general, infectious causes of spinal cord dysfunction are rare, but outbreaks of AFM serve as a reminder of the myelitis outbreaks seen during poliovirus outbreaks. (See  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome"</a>.)</p><p class="headingAnchor" id="H1959534226"><span class="h2">Paraneoplastic syndromes</span><span class="headingEndMark"> — </span>Paraneoplastic myelopathy can present as a rapidly progressive spastic paresis with or without bowel and bladder dysfunction. It often occurs in association with involvement of other areas of the nervous system; examples include encephalitis, sensory neuronopathy, chorea, and optic neuropathy.</p><p>Paraneoplastic myelopathy can also occur as an isolated syndrome. The most commonly associated antibodies are anti-Hu, anti-collapsin-responsive mediator protein 5 (CRMP5), and, less frequently, anti-amphiphysin antibodies. The usual associated malignancy is small cell lung cancer (SCLC). (See  <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Spinal cord syndromes'</a>.)</p><p class="headingAnchor" id="H1786385276"><span class="h2">Vaccinations</span><span class="headingEndMark"> — </span>TM has been reported to occur in association with vaccination, but causation has not been established based on the timing and sequence of events alone [<a href="#rid41">41-44</a>]. In one retrospective study of 47 children with acute TM, vaccination within 30 days prior to the onset of TM symptoms was reported in 28 percent [<a href="#rid44">44</a>]. There were no patterns in the illness or vaccine history that correlated with the acute onset of disease.</p><p>In a database from the United States, with 64 million vaccine doses administered among children and adults from 2007 through 2012, there were only seven subjects with TM who were vaccinated during the primary exposure interval of 5 to 28 days prior to TM onset [<a href="#rid43">43</a>]. Comparing each TM case with all matched subjects in the exposure interval who received the same vaccination, there was no association of TM with prior vaccination.</p><p class="headingAnchor" id="H1398395199"><span class="h2">Idiopathic</span><span class="headingEndMark"> — </span>TM is considered idiopathic when the cause is not identified despite a comprehensive evaluation. Idiopathic TM accounts for 15 to 30 percent of TM cases [<a href="#rid23">23,45-47</a>]. These wide discrepancies in the frequency of idiopathic TM may reflect variation in catchment area populations, disease definitions, and the evolution of diagnostic methods.</p><p>There is an antecedent respiratory, gastrointestinal, or systemic illness in 30 to 60 percent of idiopathic TM cases [<a href="#rid48">48-54</a>]. Nevertheless, these are considered idiopathic because the causative nature of the infection is seldom proven.</p><p class="headingAnchor" id="H12689882"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>TM is a rare disorder with a reported incidence between one and nine cases per million people per year [<a href="#rid55">55-57</a>]; this is probably an underestimate. These numbers imply that approximately 1400 new cases occur in the United States per year and that approximately 34,000 people have chronic morbidity from TM at any time [<a href="#rid48">48-50</a>].</p><p>A bimodal peak between the ages of 10 and 19 years and between 30 and 39 years has been reported [<a href="#rid48">48-50</a>]. Approximately 20 percent of cases are under the age of 18 years [<a href="#rid44">44</a>]. One report of acute TM in children found a bimodal distribution by age even among patients younger than 18 years of age, and a higher peak under the age of 3, with no sex predisposition [<a href="#rid44">44</a>].</p><p>There is no sex or familial predisposition to TM, although females predominate among the cases that are associated with multiple sclerosis [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H190496510"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2587867449"><span class="h2">Acute myelopathy</span><span class="headingEndMark"> — </span>TM affects spinal cord function at one or more levels and causes a segmental syndrome. The head and face are not affected. There is loss of sensory modalities and/or weakness below the affected spinal cord level with associated bladder dysfunction. Loss of function may be total or incomplete. (See  <a class="medical medical_review" href="/z/d/html/5110.html" rel="external">"Anatomy and localization of spinal cord disorders", section on 'Segmental syndrome'</a>.)</p><p class="headingAnchor" id="H3860296795"><span class="h2">Onset and progression</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presenting symptoms</strong> – The onset of TM is characterized by acute or subacute development of neurologic signs and symptoms consisting of motor, sensory, and/or autonomic dysfunction. In a survey with data for over 470 individuals with idiopathic TM, the most common initial symptoms were [<a href="#rid59">59</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensory change – 39 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Weakness – 25 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Pain (mainly back pain) – 22 percent</p><p></p><p class="bulletIndent1">Bladder and bowel symptoms and balance problems were less frequent first symptoms [<a href="#rid59">59</a>]. Presentation with pain or weakness was more common in children (n = 70) than in adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression to nadir</strong> – In most patients with idiopathic or secondary TM, the time to the maximal neurologic deficit before improvement or plateau (ie, the nadir) is within 1 to 21 days [<a href="#rid1">1,2,46,60</a>]. In a retrospective series of 47 children with TM, the mean time to nadir from the onset of acute symptoms was approximately two days [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maximal deficits</strong> – In a series of 47 children with TM, symptoms of sensory loss or numbness, weakness, urinary dysfunction, or pain were present in 91, 89, 85, and 75 percent of children, respectively [<a href="#rid44">44</a>]. Most (89 percent) of the children required a wheelchair or were confined to bed in the initial phase of TM; note that this series was published in 2007 before myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibody testing was generally available. Symptoms at nadir tend to be less severe with multiple sclerosis-associated TM, while symptoms tend to be moderate to severe (eg, requiring an ambulatory aid) with seropositive neuromyelitis optica spectrum disorder (NMOSD)- or MOG antibody-associated disease (MOGAD)-associated TM [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Most patients experience variable degrees of subsequent improvement, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/142457.html" rel="external">"Transverse myelitis: Treatment and prognosis", section on 'Recovery'</a>.)</p><p></p><p class="headingAnchor" id="H334042231"><span class="h2">Motor symptoms</span><span class="headingEndMark"> — </span>Motor symptoms include a rapidly progressing paraparesis or quadriparesis, depending on location of the lesion within the spinal cord [<a href="#rid4">4,5,52</a>]. Accompanying symptoms may include paroxysmal tonic spasms of the trunk or extremities (especially with seropositive NMOSD-associated TM) [<a href="#rid2">2</a>].</p><p>In most cases caused by white matter damage, there is initial flaccidity followed by spasticity. Gray matter involvement leads to persistent flaccid weakness.</p><p class="headingAnchor" id="H3424591505"><span class="h2">Sensory symptoms</span><span class="headingEndMark"> — </span>Most patients have a sensory level (a dermatomal level at which sensation is normal above and reduced or absent below). In one series of 170 patients with idiopathic TM, a thoracic clinical sensory level was identified in 63 percent of the patients. Another series of 47 children with acute TM reported a thoracic clinical sensory level in 53 percent [<a href="#rid44">44</a>]. In addition to sensory loss, other typical sensory symptoms include pain, dysesthesia, and paresthesias, although paresthesias are uncommon in children [<a href="#rid4">4,61</a>]. Some patients have Lhermitte sign (a transient electric sensation radiating down the spine or into the limbs with neck flexion) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1941563909"><span class="h2">Autonomic symptoms</span><span class="headingEndMark"> — </span>Autonomic symptoms include increased urinary urgency, bladder and bowel incontinence, difficulty with voiding or inability to void, bowel constipation, and sexual dysfunction [<a href="#rid4">4,62-64</a>].</p><p class="headingAnchor" id="H1735584586"><span class="h1">IMAGING FEATURES</span></p><p class="headingAnchor" id="H16819182"><span class="h2">Spine imaging</span><span class="headingEndMark"> — </span>In patients with TM, MRI of the spinal cord typically shows a gadolinium-enhancing signal abnormality  (<a class="graphic graphic_diagnosticimage graphicRef73197" href="/z/d/graphic/73197.html" rel="external">image 1</a>), usually extending over one or more cord segments [<a href="#rid44">44,48,65,66</a>]. The cord often appears swollen at the affected levels. In an adult case series of 170 patients with idiopathic TM, MRI T2-weighted imaging showed a cervical signal abnormality in 44 percent and a thoracic signal abnormality in 37 percent; the rostral-caudal extent of the lesion ranged from one vertebral segment in many to the entire spinal cord in two patients [<a href="#rid67">67</a>]. A similar pattern was seen in children, with the average lesion spanning six segments [<a href="#rid44">44</a>]. Since these reports [<a href="#rid44">44,67</a>] predate the widespread use of anti-myelin oligodendrocyte glycoprotein (MOG) and anti-aquaporin-4 (AQP4) antibody testing, it is not possible to confirm if all included patients truly had idiopathic TM.</p><p>The extent and pattern of enhancement of the spinal cord lesion on MRI  (<a class="graphic graphic_diagnosticimage graphicRef131863" href="/z/d/graphic/131863.html" rel="external">image 2</a>) can suggest the underlying cause of TM.</p><p class="bulletIndent1"><span class="glyph">●</span>Short acute lesions, less than three vertebral segments, are suggestive of multiple sclerosis, especially when associated with multiple short T2 hyperintense peripheral lesions within the spinal cord. Acute lesions are usually enhancing. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'Spinal cord MRI'</a>.)</p><p></p><p class="bulletIndent1">Short lesions are less common with neuromyelitis optica spectrum disorder (NMOSD) or MOG antibody-associated disease (MOGAD). (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'Spinal cord MRI'</a> and  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'MRI spinal cord'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longitudinally extensive transverse myelitis (LETM), with lesions extending three or more vertebral segments, is typical in NMOSD, is common in MOGAD, and is more common than short lesions in acute disseminated encephalomyelitis (ADEM), particularly with MOGAD-associated ADEM. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'Spinal cord MRI'</a> and  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'MRI spinal cord'</a> and  <a class="medical medical_review" href="/z/d/html/14087.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in adults", section on 'Neuroimaging'</a> and  <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Neuroimaging'</a>.)</p><p></p><p class="bulletIndent1">Long spinal cord lesions may also be seen in myelitis due to sarcoidosis and paraneoplastic syndromes [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Myelopathy'</a>.)</p><p></p><p class="headingAnchor" id="H1437485135"><span class="h2">Brain imaging</span><span class="headingEndMark"> — </span>In appropriate clinical settings, brain MRI findings can help distinguish the different central nervous system (CNS) demyelinating disorders. The pattern of lesions with these disorders is described in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>With multiple sclerosis, brain lesions are typically found in the periventricular region, corpus callosum, centrum semiovale, brainstem, cerebellum, spinal cord, and, to a lesser extent, deep white matter structures and basal ganglia. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'Magnetic resonance imaging'</a> and  <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis", section on 'MRI'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With NMOSD, MRI of the brain on presentation is often normal, aside from optic nerve enhancement. Over time, however, brain involvement develops in many, with lesions in the central medulla, hypothalamus, diencephalon, and/or subcortical white matter. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'MRI of the brain and orbits'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With MOGAD, different phenotypes have different patterns of lesions on MRI. With optic neuritis, orbital MRI typically shows unilateral or bilateral optic nerve enhancement. With an ADEM phenotype, brain MRI typically shows multiple large, poorly demarcated T2 hyperintense lesions in white matter, deep gray matter, the brainstem, and/or middle cerebellar peduncles. (See  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'MRI orbits'</a> and  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'MRI brain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With ADEM, with or without seropositivity for MOG immunoglobulin G (IgG) autoantibody, brain MRI typically shows bilateral, asymmetric, poorly demarcated T2 hyperintense lesions in white matter, deep gray matter, the brainstem, and/or middle cerebellar peduncles. (See  <a class="medical medical_review" href="/z/d/html/14087.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in adults", section on 'Neuroimaging'</a> and  <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Neuroimaging'</a>.)</p><p></p><p class="headingAnchor" id="H12689889"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H2155012595"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of TM is suspected when there are acute or subacute signs and symptoms of motor, sensory, and/or autonomic dysfunction that localize to one or more contiguous spinal cord segments in patients with no evidence of a compressive cord lesion on imaging.</p><p class="headingAnchor" id="H800598143"><span class="h2">History</span><span class="headingEndMark"> — </span>The first step is to determine from the history and examination (see <a class="local">'Clinical features'</a> above) whether the condition is likely to be a myelopathy.</p><p>Symptoms that should cause a clinician to consider a myelopathy include weakness and sensory loss in a myelopathic distribution, accompanied by bowel/bladder incontinence and urinary retention. Any of these symptoms should at least raise the possibility of a myelopathy and a consideration for MRI of the spine.</p><p>The history should be explored for important preceding factors such as systemic or central nervous system (CNS) autoimmune disorders and antecedent respiratory, gastrointestinal (especially chronic liver disease), or systemic illness. Additional factors to question include prior treatments (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, immune checkpoint inhibitors, tumor necrosis factor-alpha inhibitors, radiotherapy) or substance use (eg, heroin, <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a>) that may cause myelopathy [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H3827380524"><span class="h2">Examination</span><span class="headingEndMark"> — </span>On examination, localization of neurologic dysfunction is always important; a spinal cord lesion may be suspected when there are motor and/or sensory signs or symptoms that do not involve the head or face. CNS motor deficits are characterized by weakness and long tract signs (eg, spasticity, increased reflexes, Babinski sign). A spinal cord sensory level, with normal sensation above and reduced or absent sensation below, can also often be identified and should be specifically sought. Any patient with a reported or identified sensory level should be considered to have a myelopathy until proven otherwise. (See  <a class="medical medical_review" href="/z/d/html/5110.html" rel="external">"Anatomy and localization of spinal cord disorders", section on 'Clinical localization'</a>.)</p><p>When the pathology is localized, these findings will be present in muscle groups innervated below the corresponding spinal cord level and will be normal above that level. Gray matter involvement of the cord can lead to a lower motor neuron pattern of weakness (flaccid weakness, lost reflexes).</p><p>Clinically, it is impossible to differentiate a peripheral motor neuropathy leading to weakness from an anterior horn cell pathology leading to motor weakness. Thus, in the right setting, imaging must be considered in all patients with weakness.</p><p class="headingAnchor" id="H4262933150"><span class="h2">Urgent spine imaging</span><span class="headingEndMark"> — </span>When myelopathy is suspected, urgent spinal imaging is warranted to exclude a compressive lesion and to distinguish between different types of myelopathy. Imaging of the entire spinal cord is indicated, even in patients with paraplegia, due to the potential for cervical cord lesions to cause isolated lower extremity symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI of the entire spine</strong> – MRI of the entire spine, with and without gadolinium, is the preferred diagnostic study for suspected TM  (<a class="graphic graphic_algorithm graphicRef88920" href="/z/d/graphic/88920.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">In addition, diffusion-weighted imaging (DWI) of the spine should be added for patients with hyperacute (&lt;12 hours) or acute onset of myelopathic symptoms to look for evidence of spinal cord infarction [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1117.html" rel="external">"Spinal cord infarction: Clinical presentation and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternatives if urgent MRI not available</strong> – Computed tomography (CT) or CT myelogram of the spine are reasonable alternatives to exclude spinal cord compression if an MRI is contraindicated or if an MRI cannot be obtained immediately. However, a normal CT does <strong>not</strong> rule out an intrinsic spinal cord lesion.</p><p></p><p>Patients with imaging evidence of acute spinal cord compression require urgent definitive treatment to prevent further deterioration.</p><p class="headingAnchor" id="H2645681046"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3010624938"><span class="h2">Is the myelopathy inflammatory?</span><span class="headingEndMark"> — </span>If a compressive myelopathy is ruled out, the clinician should determine whether the myelopathy is inflammatory or noninflammatory. (See <a class="local">'Additional studies for the cause of myelopathy'</a> below.)</p><p>The best surrogate markers for inflammation are an inflammatory cerebrospinal fluid (ie, with pleocytosis and/or an elevated immunoglobulin G [IgG] index) or a spinal MRI demonstrating active breakdown of the blood-brain barrier (ie, with a gadolinium-enhancing lesion).</p><p>However, postcontrast enhancement and cerebrospinal fluid (CSF) pleocytosis can be seen in the setting of vascular myelopathies and hence are not specific for TM. Thus, the patient's history, MRI findings, and CSF findings must all be considered when determining if the presentation fits best for TM.</p><p class="headingAnchor" id="H1064526205"><span class="h2">Diagnostic criteria for TM</span><span class="headingEndMark"> — </span>Although a set of diagnostic criteria for TM  (<a class="graphic graphic_table graphicRef88914" href="/z/d/graphic/88914.html" rel="external">table 3</a>) has been developed for research purposes, not all are necessarily required to make the diagnosis in clinical practice [<a href="#rid46">46,69</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sensory, motor, or autonomic dysfunction attributable to the spinal cord</p><p class="bulletIndent1"><span class="glyph">●</span>T2 hyperintense signal change on spinal MRI</p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of compressive cord lesion</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral signs and/or symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Clearly defined sensory level</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammation defined by CSF pleocytosis, elevated IgG index, or gadolinium enhancement on MRI</p><p class="bulletIndent1"><span class="glyph">●</span>Progression to maximal neurologic deficit (nadir) between 4 hours and 21 days</p><p></p><p>The most critical of these are the first three. The diagnosis of TM requires exclusion of a compressive cord lesion, usually by MRI.</p><p>The diagnosis is supported by the presence of inflammation as determined by either gadolinium-enhanced MRI or lumbar puncture. However, some patients presenting with TM may not fulfill all of the above criteria. As an example, a significant percentage of individuals with a clinical pattern that otherwise resembles TM do not meet the inflammatory features; therefore, the absence of inflammatory markers does not rule out TM [<a href="#rid27">27</a>]. Furthermore, some mimics of TM, specifically vascular myelopathies, can have signal change on MRI and pleocytosis within the CSF.</p><p>Thus, a clinical history is critical for narrowing down the diagnosis. For example, patients with a history of rapid symptom progression (&lt;6 hours) should be suspected of having a vascular etiology (although some nonvascular pathologies can present acutely). A prior history of other inflammatory events (eg, optic neuritis) is suggestive of systemic autoimmune diseases such as multiple sclerosis or neuromyelitis optica spectrum disorder (NMOSD).</p><p class="headingAnchor" id="H1049039031"><span class="h1">DETERMINING THE CAUSE OF TM</span><span class="headingEndMark"> — </span>When an inflammatory myelopathy (ie, TM) is confirmed, it is important to distinguish idiopathic TM from secondary (disease-associated) TM, such as a multifocal central nervous system (CNS) inflammatory demyelinating disease, a rare infection of the nervous system, a systemic rheumatologic disease, or a paraneoplastic syndrome.</p><p>Idiopathic TM is defined by its occurrence without a definitive etiology despite a thorough work-up.</p><p>The diagnostic approach to noncompressive myelopathy  (<a class="graphic graphic_algorithm graphicRef88920" href="/z/d/graphic/88920.html" rel="external">algorithm 1</a>), including TM, emphasizes the determination of distinct entities that are likely to have different treatment options, recurrence risks, and prognoses [<a href="#rid46">46,69</a>].</p><p class="headingAnchor" id="H1278520100"><span class="h2">Additional studies for the cause of myelopathy</span><span class="headingEndMark"> — </span>For patients without a compressive cord lesion on spine imaging, additional studies are warranted to determine the cause of myelopathy and evaluate for inflammatory conditions that can cause TM.</p><p class="headingAnchor" id="H3082009676"><span class="h3">Lumbar puncture</span><span class="headingEndMark"> — </span>For patients without a compressive cord lesion on spine imaging, we perform a lumbar puncture for cerebrospinal fluid (CSF) analysis including (at a minimum) cell count and differential, protein, glucose, Venereal Disease Research Laboratory (VDRL) test, oligoclonal bands, immunoglobulin G (IgG) index, and cytology. Additional CSF studies are warranted if there is suspicion for an infectious etiology.</p><p>CSF is abnormal in approximately one-half of patients, with a moderate lymphocytosis (typically &lt;100/microL) and an elevated protein level (usually 100 to 120 mg/dL). Glucose levels are normal. In a case series of 170 adult patients with idiopathic TM, the mean CSF white blood cell count was 38/microL and mean protein level was 75 mg/dL (0.75 g/L) [<a href="#rid67">67</a>]. However, higher levels were observed in a pediatric case series, where the mean white cell count was 136/microL and the mean protein level was 173 mg/dL (1.73 g/L) [<a href="#rid44">44</a>].</p><p>Oligoclonal bands in CSF are found in 85 to 95 percent of patients with multiple sclerosis but are typically absent in patients with anti-aquaporin-4 (AQP4) antibody-mediated neuromyelitis optica spectrum disorder (NMOSD) or acute disseminated encephalomyelitis (ADEM).</p><p class="headingAnchor" id="H1242219073"><span class="h3">Brain MRI</span><span class="headingEndMark"> — </span>For patients with suspected myelopathy of undetermined cause in whom a compressive or other structural spinal cord lesion has been ruled out by initial imaging, we obtain a brain MRI, with and without gadolinium, to evaluate for the presence of brain and/or optic nerve lesions suggestive of multiple sclerosis, NMOSD, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), ADEM, or systemic inflammatory disorders that can involve the CNS.</p><p class="headingAnchor" id="H3938149004"><span class="h3">Serologic tests and autoantibodies</span><span class="headingEndMark"> — </span>Serologic studies are indicated when the cause of myelopathy remains undetermined [<a href="#rid2">2,60,70</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoantibodies</strong>:</p><p class="bulletIndent2"><span class="glyph">•</span>Serum AQP4-IgG and MOG-IgG by cell-based assay</p><p class="bulletIndent2"><span class="glyph">•</span>Antinuclear antibodies (ANA), double-stranded deoxyribonucleic acid (ds-DNA)</p><p class="bulletIndent2"><span class="glyph">•</span>Antibodies to extractable nuclear antigen (Ro/SSA, and La/SSB antibodies)</p><p class="bulletIndent2"><span class="glyph">•</span>Rheumatoid factor</p><p class="bulletIndent2"><span class="glyph">•</span>Antiphospholipid antibodies</p><p class="bulletIndent2"><span class="glyph">•</span>Antineutrophil cytoplasmic antibodies</p><p class="bulletIndent2"><span class="glyph">•</span>Paraneoplastic antibodies  (<a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory markers</strong>:</p><p class="bulletIndent2"><span class="glyph">•</span>Erythrocyte sedimentation rate</p><p class="bulletIndent2"><span class="glyph">•</span>C-reactive protein</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic work-up</strong>:</p><p class="bulletIndent2"><span class="glyph">•</span>Serum copper and ceruloplasmin levels</p><p class="bulletIndent2"><span class="glyph">•</span>Serum cobalamin (vitamin B12), folate, methylmalonic acid, and homocysteine levels</p><p class="bulletIndent2"><span class="glyph">•</span>Serum alpha tocopherol (vitamin E) level</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious work-up</strong>:</p><p class="bulletIndent2"><span class="glyph">•</span>Enterovirus serologies including D68</p><p class="bulletIndent2"><span class="glyph">•</span>HIV serology</p><p class="bulletIndent2"><span class="glyph">•</span>Syphilis serologies</p><p class="bulletIndent2"><span class="glyph">•</span>Lyme disease serology</p><p class="bulletIndent2"><span class="glyph">•</span>Varicella zoster virus (VZV) serology</p><p class="bulletIndent2"><span class="glyph">•</span>Human T-lymphotropic virus 1 (HTLV-1) serology</p><p class="bulletIndent2"><span class="glyph">•</span>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test</p><p></p><p class="headingAnchor" id="H2709214824"><span class="h3">Other studies in select patients</span><span class="headingEndMark"> — </span>Select patients may need additional testing [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chest CT scan to evaluate for evidence of sarcoidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Salivary gland biopsy if high suspicion for Sjögren's disease but negative SSA/SSB antibody</p><p class="bulletIndent1"><span class="glyph">●</span>Neuro-ophthalmologic evaluation to look for evidence of optic neuritis</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal angiogram in the setting of hyperacute myelopathies that are thought to be consistent with vascular myelopathies</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for occult malignancy (see  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'</a>)</p><p></p><p class="headingAnchor" id="H125894649"><span class="h2">Clues to specific inflammatory causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNS inflammatory demyelinating disorders</strong> – Clinical and imaging evidence (see <a class="local">'Imaging features'</a> above) of multifocal involvement within the CNS raise suspicion for TM associated with the following inflammatory demyelinating disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple sclerosis (see  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuromyelitis optica spectrum disorder (NMOSD) (see  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (see  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute disseminated encephalomyelitis (ADEM) (see  <a class="medical medical_review" href="/z/d/html/14087.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic inflammatory disorders</strong> – Conditions that cause systemic inflammation, such as systemic lupus erythematosus, sarcoidosis, or Sjögren's disease, can present with TM as an initial event. Suspicion for a systemic inflammatory disorder is increased if the patient has certain clinical or paraclinical findings such as malar rash, livedo reticularis, serositis, night sweats, oral ulcers, or autoimmune antibodies. MRI findings can be instructive, as sarcoidosis often causes meningeal inflammation at the level of parenchymal involvement in the spinal cord.</p><p></p><p class="bulletIndent1">Note that NMOSD is frequently associated with systemic autoimmune disorders, including systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's disease, and may be associated with cancer. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic syndromes</strong> – Paraneoplastic myelopathies are often associated with longitudinally extensive transverse myelitis (LETM) on spine MRI that is tract-specific [<a href="#rid71">71,72</a>]. The most common antibodies include anti-Hu and anti-collapsin-responsive mediator protein 5 (CRMP5), and, less frequently, anti-amphiphysin antibodies  (<a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">table 4</a>). The usual associated malignancy is small cell lung cancer (SCLC). (See  <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Spinal cord syndromes'</a>.)</p><p></p><p class="bulletIndent1">Patients suspected of having a paraneoplastic neurologic syndrome should be examined for paraneoplastic antibodies, and an evaluation for underlying malignancy should be performed (see  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'</a>). In some cases, however, the paraneoplastic syndrome may precede the diagnosis of underlying malignancy.</p><p></p><p class="bulletIndent1">The evaluation and diagnosis of paraneoplastic syndromes is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious causes</strong> – Although rare, a CNS infection  (<a class="graphic graphic_table graphicRef121798" href="/z/d/graphic/121798.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef121799" href="/z/d/graphic/121799.html" rel="external">table 2</a>) may be suspected with certain clinical or paraclinical factors, such as fever, meningismus, vesicular rash, adenopathy, or serologic or molecular identification of an infectious agent. (See <a class="local">'Serologic tests and autoantibodies'</a> above.)</p><p></p><p class="bulletIndent1">The initial presentation of acute flaccid myelitis (AFM) can mimic inflammatory causes of acute TM [<a href="#rid73">73</a>]. Characteristic features of AFM include a febrile or respiratory illness before the onset of neurologic symptoms followed by acute flaccid limb weakness with evolution of weakness over hours to days. MRI of the spine shows evidence of predominantly gray matter involvement in the spinal cord. (See  <a class="medical medical_review" href="/z/d/html/126102.html" rel="external">"Acute flaccid myelitis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/126102.html" rel="external">"Acute flaccid myelitis", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1">Paralytic polio consists of acute flaccid weakness with pain due to anterior horn cell injury. The onset of weakness and pain may either coincide with or follow onset of severe illness. Paralytic polio develops in approximately 0.5 to 0.05 percent (1 in 200 to 1 in 2000) of individuals infected with poliovirus. The acute flaccid weakness ranges from one muscle or group of muscles to quadriplegia and respiratory failure. Proximal muscles usually are affected more than distal muscles, and legs more commonly than arms. Reflexes are decreased or absent. (See  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H201252183"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The main considerations in the differential diagnosis of TM are conditions that cause other types of myelopathy (eg, compressive or noninflammatory) and nonmyelopathic disorders that may mimic TM (eg, Guillain-Barré syndrome). The prognosis, risk of recurrence, and treatment options differ between these distinct entities.</p><p>In a retrospective report from a tertiary center of 1193 patients referred between 2006 and 2021 for evaluation of TM, there were 421 with a noninflammatory myelopathy; among these, the most frequent diagnoses were spinal cord infarction in 47 percent and structural myelopathy (eg, cervical spondylosis, disc herniation, spinal cord syrinx) in 26 percent [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H1496149727"><span class="h2">Time to nadir</span><span class="headingEndMark"> — </span>The time from onset of symptoms to maximal neurologic deficit (nadir) is useful in narrowing the differential diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span>With idiopathic or secondary TM, the time to nadir is typically within 1 to 21 days.</p><p class="bulletIndent1"><span class="glyph">●</span>With spinal cord infarction, the time to nadir is usually within 1 to 12 hours.</p><p></p><p>Other types of myelopathy may continue to progress beyond 21 days; examples include cervical spondylotic myelopathy, dural arteriovenous fistula, paraneoplastic myelopathy, metabolic myelopathy, and primary progressive multiple sclerosis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord"</a>.)</p><p class="headingAnchor" id="H3819515274"><span class="h2">Compressive myelopathy</span><span class="headingEndMark"> — </span>Disc herniations, vertebral body compression fractures, and spondylosis are among the most common causes of compressive myelopathy. They may present without overt evidence or history of trauma. Identifying these disorders is critical since immobilization to prevent further injury, neurosurgical intervention, and/or high-dose <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> may be warranted in certain cases. Therefore, urgent imaging of the entire spine with MRI is indicated. (See <a class="local">'Urgent spine imaging'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cervical spondylotic myelopathy</strong> – The diagnosis of cervical spondylotic myelopathy is made by correlating the clinical features with evidence of cervical spondylosis and cord compression on MRI. (See  <a class="medical medical_review" href="/z/d/html/4820.html" rel="external">"Cervical spondylotic myelopathy", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis arachnoiditis</strong> – Tuberculosis arachnoiditis of the spine is another potential cause of compressive myelopathy and is more common in developing countries than in the United States. The diagnosis should be suspected in patients with subacute onset of nerve root and cord compression signs who have a history of prior tuberculosis (TB) infection or disease, known or possible TB exposure, and/or past or present residence in or travel to an area where TB is endemic. A presumptive diagnosis may be made in the setting of spinal MRI with nodular arachnoiditis and unusually high cerebrospinal fluid (CSF) protein levels, with or without pleocytosis, particularly if a definitive diagnosis of TB has been established from an extraneural site of disease. (See  <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">"Central nervous system tuberculosis: An overview", section on 'Spinal arachnoiditis'</a>.)</p><p></p><p class="headingAnchor" id="H803267993"><span class="h2">Vascular myelopathies</span><span class="headingEndMark"> — </span>Vascular conditions that may present acutely (over hours) include spinal cord infarction (anterior or posterior spinal artery), spinal dural arteriovenous fistula, and hemorrhage (hematomyelia, epidural hematoma) [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal cord infarction</strong> – The diagnosis of spinal cord infarction is made in the setting of a compatible clinical syndrome, typically with rapidly developing myelopathic deficits in the absence of another identifiable etiology. Spine MRI findings have imperfect sensitivity and specificity for ischemia. However, diffusion-weighted images (DWI-MRI) improve the sensitivity of MRI to detect acute spinal ischemia. (See  <a class="medical medical_review" href="/z/d/html/1117.html" rel="external">"Spinal cord infarction: Clinical presentation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dural arteriovenous fistula</strong> – Spinal-dural arteriovenous fistula predominately occurs in men 60 years of age and older, and typically presents with a progressive, stepwise myeloradiculopathy. MRI with contrast-enhanced magnetic resonance angiography (MRA) can identify a dural arteriovenous fistula but has imperfect sensitivity. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Vascular malformations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidural hematoma</strong> – Spinal epidural hematoma typically presents with local and/or radicular pain, followed by loss of sensory, motor, and bladder and bowel function. MRI is a sensitive imaging modality for these lesions. MRI findings vary according to the age of the clot, as described separately. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Spinal epidural hematoma'</a>.)</p><p></p><p class="headingAnchor" id="H2500920968"><span class="h2">Metabolic and toxic myelopathies</span><span class="headingEndMark"> — </span>These disorders generally present with a chronic progressive course but may have a subacute onset or worsening [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic</strong> – Metabolic myelopathies include copper deficiency myeloneuropathy, subacute combined degeneration due to vitamin B12 deficiency, and vitamin E deficiency [<a href="#rid68">68,74</a>]. Testing (serum copper and ceruloplasmin levels; cobalamin [vitamin B12], folate, methylmalonic acid, and homocysteine levels; and alpha tocopherol [vitamin E] level) should be obtained to exclude these potentially treatable disorders. These conditions are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/16517.html" rel="external">"Copper deficiency myeloneuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Subacute combined degeneration'</a> and  <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic</strong> – Toxic myelopathies include those caused by <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, tumor necrosis factor-alpha medications, immune checkpoint inhibitors, radiation therapy, hepatic myelopathy leading to accumulation of toxins, substance use (<a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a> toxicity, heroin), and decompression myelopathy due to prolonged-duration diving with rapid ascent.</p><p></p><p class="bulletIndent1">Radiation myelopathy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7066.html" rel="external">"Complications of spinal cord irradiation"</a>.)</p><p></p><p class="bulletIndent1">Rare toxic myelopathies caused by diet include neurolathyrism due to neurotoxins in diets consisting mainly of Lathyrus species, as well as konzo due to cyanogens in diets consisting mainly of bitter cassava. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Lathyrism and konzo'</a>.)</p><p></p><p class="headingAnchor" id="H2361159283"><span class="h2">Neoplastic myelopathies</span><span class="headingEndMark"> — </span>Both benign and malignant tumors can produce a myelopathy because of external spinal cord compression or intramedullary growth. Tumor types include primary spinal cord astrocytoma, ependymoma, primary intramedullary spinal cord lymphoma, and metastatic disease. Progression is often chronic (beyond 21 days), but subacute onset or worsening can occur. MRI of the entire spine with contrast can identify extradural tumors causing cord compression and intramedullary spinal cord tumors causing myelopathy. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Neoplasms'</a>.)</p><p class="headingAnchor" id="H167018386"><span class="h2">Guillain-Barré syndrome</span><span class="headingEndMark"> — </span>Patients with acute inflammatory demyelinating polyneuropathy (AIDP), the most common form of Guillain-Barré syndrome (GBS), may also present with progressive sensory and motor dysfunction [<a href="#rid75">75</a>]. However, several clinical and paraclinical features may be used to rapidly discriminate patients with AIDP from those with acute myelopathies  (<a class="graphic graphic_table graphicRef88912" href="/z/d/graphic/88912.html" rel="external">table 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with AIDP often have both upper and lower extremity involvement, though the lower extremity involvement is usually more severe. By contrast, patients with myelopathy may have only lower extremity involvement if the myelopathy is thoracic, or equivalent upper and lower extremity involvement if the myelopathy is cervical.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic involvement differs. Patients with myelopathy are more likely to have urinary or bowel urgency or retention, while those with AIDP are more likely to have cardiovascular instability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Every attempt should be made to determine a neuropathic versus myelopathic pattern of sensory loss, since a sensory level is often definable in patients with acute myelopathy but is never present in AIDP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSF analysis in AIDP usually shows an elevated protein with few white cells (ie, cytoalbuminologic dissociation), whereas patients with TM may have an inflammatory CSF with an elevated number of white blood cells and immunoglobulin G (IgG) index.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spinal MRI often shows a discrete cord lesion in myelopathy, whereas spinal MRI may be normal in AIDP. Spinal MRI in patients with GBS may reveal thickening and enhancement of the intrathecal spinal nerve roots and cauda equina. This may involve only the anterior spinal nerve roots or both the anterior and posterior spinal nerve roots. In exceptional cases of Miller Fisher syndrome, abnormalities of the spinal cord posterior columns have been described. However, these findings may have occurred in patients with variants of myelitis that were misinterpreted as peripheral inflammatory neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrodiagnostic studies may show conduction block or slowed conduction of peripheral nerves in AIDP and are usually (though not always) normal in myelopathies.</p><p></p><p>GBS is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H173924543"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H190497614"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>– Acute transverse myelitis (TM) is a neuroinflammatory spinal cord disorder that presents with the rapid onset of weakness, sensory alterations, and/or bowel and bladder dysfunction. Idiopathic TM is defined by its occurrence without a definitive etiology despite a thorough work-up. Secondary (disease-associated) TM is most often related to a systemic inflammatory autoimmune condition. (See <a class="local">'Immunopathogenesis'</a> above and <a class="local">'Terminology and classification'</a> above.)</p><p></p><p class="bulletIndent1">TM is rare, with an annual incidence of one to nine new cases per million. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Idiopathic TM often occurs as a postinfectious complication and presumably results from an autoimmune process. Alternatively, TM can be associated with infectious  (<a class="graphic graphic_table graphicRef121798" href="/z/d/graphic/121798.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef121799" href="/z/d/graphic/121799.html" rel="external">table 2</a>), systemic inflammatory, or multifocal central nervous system (CNS) disease.</p><p></p><p class="bulletIndent1">Acquired CNS demyelinating disorders that can cause TM include multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM). (See <a class="local">'Associated and causative conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The onset of TM is characterized by acute or subacute development of myelopathic signs and symptoms consisting of the following (see <a class="local">'Clinical features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Motor symptoms include a rapidly progressing paraparesis that can progress to quadriparesis. Initial flaccidity is followed by spasticity. The head and face are spared.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients have a sensory level (a dermatomal level at which sensation is normal above and reduce or absent below). Sensory symptoms may also include pain, dysesthesia, and paresthesia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autonomic symptoms involve increased urinary urgency, bladder and bowel incontinence, difficulty or inability to void, incomplete evacuation and bowel constipation, and sexual dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The diagnosis of TM is suspected when there are acute or subacute signs and symptoms of motor, sensory, and/or autonomic dysfunction that localize to one or more contiguous spinal cord segments in patients with no evidence of a compressive cord lesion.</p><p></p><p class="bulletIndent1">Thus, the diagnosis of TM requires exclusion of a compressive cord lesion, usually by MRI, and confirmation of inflammation by either gadolinium-enhanced MRI or lumbar puncture  (<a class="graphic graphic_algorithm graphicRef88920" href="/z/d/graphic/88920.html" rel="external">algorithm 1</a>). When inflammation is present in the absence of cord compression, the criteria for TM  (<a class="graphic graphic_table graphicRef88914" href="/z/d/graphic/88914.html" rel="external">table 3</a>) have been met.</p><p></p><p class="bulletIndent1">The evaluation next investigates the presence of infection, systemic inflammation, and the extent and sites of CNS inflammation  (<a class="graphic graphic_table graphicRef65585" href="/z/d/graphic/65585.html" rel="external">table 6</a>). (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The main considerations in the differential diagnosis of idiopathic TM and secondary (disease-related) TM are conditions that cause noninflammatory types of myelopathy (eg, compressive, vascular, metabolic, toxic myelopathies) and nonmyelopathic disorders that may mimic TM (eg, Guillain-Barré syndrome). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis</strong> – These issues are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/142457.html" rel="external">"Transverse myelitis: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H2699577943"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Douglas Kerr, MD, and Chitra Krishnan, MHS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barreras P, Fitzgerald KC, Mealy MA, et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology 2018; 90:e12.</a></li><li><a class="nounderline abstract_t">Lopez Chiriboga S, Flanagan EP. Myelitis and Other Autoimmune Myelopathies. Continuum (Minneap Minn) 2021; 27:62.</a></li><li><a class="nounderline abstract_t">Greenberg BM, Frohman EM. Immune-mediated myelopathies. Continuum (Minneap Minn) 2015; 21:121.</a></li><li><a class="nounderline abstract_t">Krishnan C, Kaplin AI, Pardo CA, et al. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep 2006; 6:236.</a></li><li><a class="nounderline abstract_t">Kaplin AI, Krishnan C, Deshpande DM, et al. Diagnosis and management of acute myelopathies. Neurologist 2005; 11:2.</a></li><li><a class="nounderline abstract_t">Lyons JL. Myelopathy associated with microorganisms. Continuum (Minneap Minn) 2015; 21:100.</a></li><li><a class="nounderline abstract_t">Brocke S, Hausmann S, Steinman L, Wucherpfennig KW. Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Semin Immunol 1998; 10:57.</a></li><li><a class="nounderline abstract_t">Bohach GA. Staphylococcal enterotoxins B and C. Structural requirements for superantigenic and entertoxigenic activities. Prep Biochem Biotechnol 1997; 27:79.</a></li><li><a class="nounderline abstract_t">Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990; 17:251.</a></li><li><a class="nounderline abstract_t">Betley MJ, Borst DW, Regassa LB. Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal pyrogenic exotoxins: a comparative study of their molecular biology. Chem Immunol 1992; 55:1.</a></li><li><a class="nounderline abstract_t">Zhang J, Vandevyver C, Stinissen P, et al. Activation and clonal expansion of human myelin basic protein-reactive T cells by bacterial superantigens. J Autoimmun 1995; 8:615.</a></li><li><a class="nounderline abstract_t">Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54:99.</a></li><li><a class="nounderline abstract_t">Vanderlugt CL, Begolka WS, Neville KL, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 1998; 164:63.</a></li><li><a class="nounderline abstract_t">PIPER PG. Disseminated lupus erythematosus with involvement of the spinal cord. J Am Med Assoc 1953; 153:215.</a></li><li><a class="nounderline abstract_t">Andrianakos AA, Duffy J, Suzuki M, Sharp JT. Transverse myelopathy in systemic lupus erythematosus. Report of three cases and review of the literature. Ann Intern Med 1975; 83:616.</a></li><li><a class="nounderline abstract_t">Nakano I, Mannen T, Mizutani T, Yokohari R. Peripheral white matter lesions of the spinal cord with changes in small arachnoid arteries in systemic lupus erythematosus. Clin Neuropathol 1989; 8:102.</a></li><li><a class="nounderline abstract_t">Sinkovics JG, Gyorkey F, Thoma GW. A rapidly fatal case of systemic lupus erythematosus: structures resembling viral nucleoprotein strands in the kidney and activities of lymphocytes in culture. Tex Rep Biol Med 1969; 27:887.</a></li><li><a class="nounderline abstract_t">WEIL MH. Disseminated lupus erythematosus with massive hemorrhagic manifestations and paraplegia. J Lancet 1955; 75:358.</a></li><li><a class="nounderline abstract_t">Haase CG, Schmidt S. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica. Neurosci Lett 2001; 307:131.</a></li><li><a class="nounderline abstract_t">Pandit L, Rao S. Recurrent myelitis. J Neurol Neurosurg Psychiatry 1996; 60:336.</a></li><li><a class="nounderline abstract_t">Tippett DS, Fishman PS, Panitch HS. Relapsing transverse myelitis. Neurology 1991; 41:703.</a></li><li><a class="nounderline abstract_t">Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106.</a></li><li><a class="nounderline abstract_t">Murphy OC, Barreras P, Villabona-Rueda A, et al. Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. J Neurol Sci 2022; 442:120425.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79:437.</a></li><li><a class="nounderline abstract_t">Scott AM, Yinh J, McAlindon T, Kalish R. Two cases of sarcoidosis presenting as longitudinally extensive transverse myelitis. Clin Rheumatol 2018; 37:2899.</a></li><li><a class="nounderline abstract_t">Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm 2020; 7.</a></li><li><a class="nounderline abstract_t">de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005; 65:1950.</a></li><li><a class="nounderline abstract_t">Anantharaju A, Baluch M, Van Thiel DH. Transverse myelitis occurring in association with primary biliary cirrhosis and Sjogren's syndrome. Dig Dis Sci 2003; 48:830.</a></li><li><a class="nounderline abstract_t">Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010; 81:213.</a></li><li><a class="nounderline abstract_t">Lehnhardt FG, Impekoven P, Rubbert A, et al. Recurrent longitudinal myelitis as primary manifestation of SLE. Neurology 2004; 63:1976.</a></li><li><a class="nounderline abstract_t">Krishnan AV, Halmagyi GM. Acute transverse myelitis in SLE. Neurology 2004; 62:2087.</a></li><li><a class="nounderline abstract_t">Boussaid S, Rahmouni S, Rekik S, et al. Acute transverse myelitis revealing ankylosing spondylitis: A case report and literature review. Clin Case Rep 2021; 9:e04878.</a></li><li><a class="nounderline abstract_t">Mori A, Nodera H, Nakane S, Kaji R. Transverse myelitis and polymyositis associated with antiphospholipid antibody syndrome. Clin Neurol Neurosurg 2010; 112:713.</a></li><li><a class="nounderline abstract_t">Ricarte IF, Dutra LA, Abrantes FF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus 2018; 27:1404.</a></li><li><a class="nounderline abstract_t">Bitik B, Ucar M, Tezcan ME, et al. Transverse myelitis in Behçet's disease: a series of four cases and review of the literature. Clin Exp Rheumatol 2013; 31:20.</a></li><li><a class="nounderline abstract_t">Lee HS, Kim do Y, Shin HY, et al. Spinal cord involvement in Behçet's disease. Mult Scler 2016; 22:960.</a></li><li><a class="nounderline abstract_t">Bhinder S, Harbour K, Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature. Clin Rheumatol 2007; 26:445.</a></li><li><a class="nounderline abstract_t">Harzheim M, Schlegel U, Urbach H, et al. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci 2004; 217:217.</a></li><li><a class="nounderline abstract_t">Torabi AM, Patel RK, Wolfe GI, et al. Transverse myelitis in systemic sclerosis. Arch Neurol 2004; 61:126.</a></li><li><a class="nounderline abstract_t">Mécharles S, Herrmann C, Poullain P, et al. Acute myelitis due to Zika virus infection. Lancet 2016; 387:1481.</a></li><li><a class="nounderline abstract_t">Patja A, Paunio M, Kinnunen E, et al. Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination. J Pediatr 2001; 138:250.</a></li><li><a class="nounderline abstract_t">Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110:105.</a></li><li><a class="nounderline abstract_t">Baxter R, Lewis E, Goddard K, et al. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis 2016; 63:1456.</a></li><li><a class="nounderline abstract_t">Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68:1474.</a></li><li><a class="nounderline abstract_t">Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin 2013; 31:79.</a></li><li><a class="nounderline abstract_t">Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59:499.</a></li><li><a class="nounderline abstract_t">de Seze J, Stojkovic T, Breteau G, et al. Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain 2001; 124:1509.</a></li><li><a class="nounderline abstract_t">Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993; 50:532.</a></li><li><a class="nounderline abstract_t">Christensen PB, Wermuth L, Hinge HH, Bømers K. Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol Scand 1990; 81:431.</a></li><li><a class="nounderline abstract_t">ALTROCCHI PH. ACUTE TRANSVERSE MYELOPATHY. Arch Neurol 1963; 9:111.</a></li><li><a class="nounderline abstract_t">Lipton HL, Teasdall RD. Acute transverse myelopathy in adults. A follow-up study. Arch Neurol 1973; 28:252.</a></li><li><a class="nounderline abstract_t">Ropper AH, Poskanzer DC. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. Ann Neurol 1978; 4:51.</a></li><li><a class="nounderline abstract_t">Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004; 128:1.</a></li><li><a class="nounderline abstract_t">PAINE RS, BYERS RK. Transverse myelopathy in childhood. AMA Am J Dis Child 1953; 85:151.</a></li><li><a class="nounderline abstract_t">Berman M, Feldman S, Alter M, et al. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981; 31:966.</a></li><li><a class="nounderline abstract_t">Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmun Rev 2010; 9:A395.</a></li><li><a class="nounderline abstract_t">Sechi E, Shosha E, Williams JP, et al. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology 2019; 93:e414.</a></li><li><a class="nounderline abstract_t">Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128.</a></li><li><a class="nounderline abstract_t">Greenberg BM, Krishnan C, Harder L. New onset transverse myelitis diagnostic accuracy and patient experiences. Mult Scler Relat Disord 2019; 30:42.</a></li><li><a class="nounderline abstract_t">Schmalstieg WF, Weinshenker BG. Approach to acute or subacute myelopathy. Neurology 2010; 75:S2.</a></li><li><a class="nounderline abstract_t">Dunne K, Hopkins IJ, Shield LK. Acute transverse myelopathy in childhood. Dev Med Child Neurol 1986; 28:198.</a></li><li><a class="nounderline abstract_t">Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturition disturbance in acute transverse myelitis. Spinal Cord 1996; 34:481.</a></li><li><a class="nounderline abstract_t">Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine (Phila Pa 1976) 2001; 26:S129.</a></li><li><a class="nounderline abstract_t">DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002; 15:271.</a></li><li><a class="nounderline abstract_t">Bakshi R, Kinkel PR, Mechtler LL, et al. Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis. Eur J Neurol 1998; 5:35.</a></li><li><a class="nounderline abstract_t">Choi KH, Lee KS, Chung SO, et al. Idiopathic transverse myelitis: MR characteristics. AJNR Am J Neuroradiol 1996; 17:1151.</a></li><li><a class="nounderline abstract_t">Krishnan C, Kaplin AI, Calabresi P, Kerr DA. Clinical characteristics and prognostic factors in 170 patients with idiopathic transverse myelitis. Neurology 2004; 62 (Suppl 5):A231.</a></li><li><a class="nounderline abstract_t">Parks NE. Metabolic and Toxic Myelopathies. Continuum (Minneap Minn) 2021; 27:143.</a></li><li><a class="nounderline abstract_t">Berger JR, Cambi F, Di Rocco A, Farace J. Overview to approach to the patient with noncompressive myelopathy. Continuum (Minneap Minn) 2005; 11:13.</a></li><li><a class="nounderline abstract_t">Toledano M. Infectious Myelopathies. Continuum (Minneap Minn) 2021; 27:93.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Keegan BM. Paraneoplastic myelopathy. Neurol Clin 2013; 31:307.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM. Immune-Mediated Myelopathies. Continuum (Minneap Minn) 2018; 24:497.</a></li><li><a class="nounderline abstract_t">Theroux LM, Brenton JN. Acute Transverse and Flaccid Myelitis in Children. Curr Treat Options Neurol 2019; 21:64.</a></li><li><a class="nounderline abstract_t">Goodman BP. Metabolic and toxic causes of myelopathy. Continuum (Minneap Minn) 2015; 21:84.</a></li><li><a class="nounderline abstract_t">Wolf VL, Lupo PJ, Lotze TE. Pediatric acute transverse myelitis overview and differential diagnosis. J Child Neurol 2012; 27:1426.</a></li></ol></div><div id="topicVersionRevision">Topic 14088 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29196574" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33522737" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Myelitis and Other Autoimmune Myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651221" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immune-mediated myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635433" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Demyelinating disorders: update on transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15631640" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnosis and management of acute myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651220" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Myelopathy associated with microorganisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9529656" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292922" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Staphylococcal enterotoxins B and C. Structural requirements for superantigenic and entertoxigenic activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2206394" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1418613" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal pyrogenic exotoxins: a comparative study of their molecular biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492354" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Activation and clonal expansion of human myelin basic protein-reactive T cells by bacterial superantigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8397479" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Superantigens and their potential role in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9795764" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The functional significance of epitope spreading and its regulation by co-stimulatory molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13069296" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disseminated lupus erythematosus with involvement of the spinal cord.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1200494" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Transverse myelopathy in systemic lupus erythematosus. Report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2721041" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Peripheral white matter lesions of the spinal cord with changes in small arachnoid arteries in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5374267" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A rapidly fatal case of systemic lupus erythematosus: structures resembling viral nucleoprotein strands in the kidney and activities of lymphocytes in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13242968" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disseminated lupus erythematosus with massive hemorrhagic manifestations and paraplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427318" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609515" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrent myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2027486" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relapsing transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589308" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36191573" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677112" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Discriminating long myelitis of neuromyelitis optica from sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29770929" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Two cases of sarcoidosis presenting as longitudinally extensive transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32269072" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical and MRI phenotypes of sarcoidosis-associated myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380618" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Idiopathic acute transverse myelitis: application of the recent diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12741480" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transverse myelitis occurring in association with primary biliary cirrhosis and Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145030" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557531" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recurrent longitudinal myelitis as primary manifestation of SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184619" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute transverse myelitis in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34631068" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute transverse myelitis revealing ankylosing spondylitis: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20493629" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Transverse myelitis and polymyositis associated with antiphospholipid antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768970" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neurologic manifestations of antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23558020" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Transverse myelitis in Behçet's disease: a series of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26480923" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Spinal cord involvement in Behçet's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391892" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706227" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14732630" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transverse myelitis in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26946926" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute myelitis due to Zika virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174624" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk of Guillain-Barrésyndrome after measles-mumps-rubella vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/463869" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27585798" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470749" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute transverse myelitis in childhood: center-based analysis of 47 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23186897" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12236201" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Proposed diagnostic criteria and nosology of acute transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11459743" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8489410" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375246" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical course and long-term prognosis of acute transverse myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14048158" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : ACUTE TRANSVERSE MYELOPATHY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4688431" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acute transverse myelopathy in adults. A follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/697326" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15450348" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13007166" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Transverse myelopathy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7196523" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute transverse myelitis: incidence and etiologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20035902" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The epidemiology of transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31235660" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156988" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30738277" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : New onset transverse myelitis diagnostic accuracy and patient experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21041766" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Approach to acute or subacute myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3709989" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Acute transverse myelopathy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856855" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Micturition disturbance in acute transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805620" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The management of neurogenic bladder and sexual dysfunction after spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045724" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10210810" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8791931" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Idiopathic transverse myelitis: MR characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical characteristics and prognostic factors in 170 patients with idiopathic transverse myelitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33522740" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Metabolic and Toxic Myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Overview to approach to the patient with noncompressive myelopathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33522738" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Infectious Myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23186906" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Paraneoplastic myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29613897" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Immune-Mediated Myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31792626" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Acute Transverse and Flaccid Myelitis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651219" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Metabolic and toxic causes of myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914370" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pediatric acute transverse myelitis overview and differential diagnosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
